Abizer Gaslightwala
Known title: CEOCIK: 0002049375
Abizer Gaslightwala's purchase track record
Abizer Gaslightwala has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/21/2025 | AKTX | $20K | -50.0% | -74.5% | +7.7% |
| 6/17/2025 | AKTX | $37K | -36.0% | -78.5% | +13.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| AKTX | ▲ Buy | Grant | 6,430 | $62K | 9/29/2026 | View on chart |
| AKTX | ▲ Buy | Open Market | 3,000 | $3K | 8/25/2025 | View on chart |
| AKTX | ▲ Buy | Open Market | 8,000 | $7K | 8/22/2025 | View on chart |
| AKTX | ▲ Buy | Open Market | 10,000 | $9K | 8/21/2025 | View on chart |
| AKTX | ▲ Buy | Open Market | 5,203 | $6K | 6/24/2025 | View on chart |
| AKTX | ▲ Buy | Open Market | 943 | $1K | 6/23/2025 | View on chart |
| AKTX | ▲ Buy | Open Market | 10,000 | $12K | 6/20/2025 | View on chart |
| AKTX | ▲ Buy | Open Market | 15,000 | $18K | 6/17/2025 | View on chart |
| AKTX | ▲ Buy | Grant | 25,000 | $30K | 6/13/2025 | View on chart |
| AKTX | ▲ Buy | Grant | 20,000 | $25K | 6/12/2025 | View on chart |
| AKTX | ▲ Buy | Grant | 20,000 | $25K | 6/10/2025 | View on chart |
| AKTX | ▲ Buy | Grant | 133,928 | $150K | 3/6/2025 | View on chart |
| AKTX | ▲ Buy | Grant | 11,439 | $14K | 1/10/2025 | View on chart |
| AKTX | ▲ Buy | Grant | 1,720,000 | $1K | 1/3/2025 | View on chart |
| AKTX | ▲ Buy | Grant | 40,000,000 | $20K | 12/27/2024 | View on chart |
| AKTX | ▲ Buy | Grant | 30,000,000 | $15K | 12/26/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Akari Therapeutics Files New Patent Application
Akari Therapeutics has submitted a new patent application to expand its intellectual property portfolio. This move is relevant as it aims to strengthen the company's long-term position in its therapeutic areas. The stock currently trades well below its 52-week high, reflecting the significant volatility seen in the sector.
Akari Therapeutics Files New Patent Application. Akari Therapeutics has submitted a new patent application to expand its intellectual property portfolio. This move is relevant as it aims to strengthen the company's long-term position in its therapeutic areas. The stock currently trades well below its 52-week high, reflecting the significant volatility seen in the sector.